

9.0 BIBLIOGRAPHY

1. GCC Lim, Y Halimah, S Rampal. Cancer Incidence in Peninsular Malaysia, 2003-2005. The Third Report of the National Cancer Registry, Malaysia.
2. Parkin MD, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. *CA Cancer J Clin* 2005; 55:74-108.
3. Parkin MD. Use of Statistics to Assess the Global Burden of Breast Cancer. *Breast Journal* 2006;12(1) (Supplement):S70-S80.
4. E.E. Elder et al. Patterns of breast cancer relapse. *EJSO* 2006; 32:922-927.
5. MOH Clinical Practice Guidelines of 'Management of Breast Cancer', Dec 2002.
6. Louise Hanna, Tom Crosby and Fergus Macbeth. *Practical Clinical Oncology*, First Edition, Cambridge University Press (2008).
7. EBCTCG. (1995). Effects of radiotherapy and surgery in early breast cancer. An Overview of the randomized trials. *N. Engl. J. Med* 333:1444-55.
8. EBCTCG. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. *Lancet* 365: 1687-717.
9. Roche H et al. Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial. *JCO* 2006 Dec 20; 24 (36):5664-5671.

10. Martin M et al. Adjuvant Docetaxel for node-positive breast cancer. *NEJM* 2005; 352:2302-13.
11. Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. *JCO* 2006 Dec 1; 24 (34) : 5381-5387.
12. The ATAC (Arimedex, Tamoxifen Alone or in Combination) Trialists Group*
Anastrozole alone or in combination with Tamoxifen versus Tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first result of the ATAC adjuvant trial. *Lancet* 2002; 359: 2131-39.
13. Kaufman M et al. Improved overall survival in postmenopausal women with early breast cancer after Anastrozole initiated treatment with Tamoxifen compared with continued Tamoxifen: The ARNO 95 Study. *JCO* 2007 July; 25(19) : 2664-2670.
14. Mouridsen H et al. Superior efficacy of Letrozole versus Tamoxifen as first line therapy for postmenopausal women with advanced breast cancer: Results of phase III study of the International Letrozole Breast Cancer Group. *JCO* 2001; 19:2596-2606.
15. Goss PE, Ingle JN, Martino S et al. A randomized trial of Letrozole in postmenopausal women after five years of Tamoxifen therapy for early-stage breast cancer. *NEJM* 2003; 349:1793-1802.
16. Smith I et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: adjuvant Controlled trial. *Lancet* 2007; 369:29-36.
17. Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N England J Med* 2005; 353:1659-72.

18. NCCN Clinical Practice Guidelines in Oncology – v.2.2006.
19. Fisher B et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. *J Clinical Oncology* 1998;16:2672-2685.
20. Imkampe A et al. The significant of the site of recurrence to subsequent breast cancer survival. *EJSO* 2007; 33:420-423.
21. Giordano SH et al. Is breast cancer surviving improving? *Cancer* 2004;100:44-52.
22. Taib NA, Yip CH, Ibrahim M. Survival Analyses of 413 Malaysian Women with Breast Cancer: Results from The University Malaya Medical Centre. *Asian Pac J Cancer Prev* 2008; 9(2): 197-202.
23. Hess KR et al. Estrogen receptors and distinct patterns of breast cancer relapse. *Breast Cancer Res Treat* 2003 Mar;78(1):105-18.
24. Hibberd AD, Horwood LJ, Wells JE. Long term prognosis of women with breast cancer in New Zealand: study of survival to 30 years. *Br Med J (Clin Res Ed)* 1983;286:1777-9.
25. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. *Br J Cancer* 1987;55:61-6.